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Abstract
Background: The apolipoprotein E (APOE) ε4 allele is the strongest genetic risk factor for late onset Alzheimer’s disease,
whilst the ε2 allele confers protection. Previous studies report differential DNA methylation of APOE between ε4 and ε2
carriers, but associations with epigenome-wide methylation have not previously been characterised.
Methods: Using the EPIC array, we investigated epigenome-wide differences in whole blood DNA methylation
patterns between Alzheimer’s disease-free APOE ε4 (n = 2469) and ε2 (n = 1118) carriers from the two largest single-
cohort DNA methylation samples profiled to date. Using a discovery, replication and meta-analysis study design,
methylation differences were identified using epigenome-wide association analysis and differentially methylated region
(DMR) approaches. Results were explored using pathway and methylation quantitative trait loci (meQTL) analyses.
Results: We obtained replicated evidence for DNA methylation differences in a ~ 169 kb region, which encompasses part of
APOE and several upstream genes. Meta-analytic approaches identified DNA methylation differences outside of APOE: differentially
methylated positions were identified in DHCR24, LDLR and ABCG1 (2.59× 10−100≤ P≤ 2.44× 10−8) and DMRs were identified in
SREBF2 and LDLR (1.63× 10−4≤ P≤ 3.01× 10−2). Pathway and meQTL analyses implicated lipid-related processes and high-density
lipoprotein cholesterol was identified as a partial mediator of the methylation differences in ABCG1 and DHCR24.
Conclusions: APOE ε4 vs. ε2 carrier status is associated with epigenome-wide methylation differences in the blood. The loci
identified are located in trans as well as cis to APOE and implicate genes involved in lipid homeostasis.
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Background
The ε4 allele of the apolipoprotein E gene (APOE) is the
strongest genetic risk factor for late-onset (> 65 years)
Alzheimer’s disease (AD) [1–3]. Inheritance of one copy
of this allele increases late-onset AD risk by two to four-
fold, with two copies conferring an eight to twelvefold
increase in risk compared to the ε3/ε3 genotype [4, 5].
The ε4 allele is also associated with a younger age-of-
onset, with ε4 homozygotes having an average age-of-
onset of 68 years compared to 84 years for ε3 homozy-
gotes [4]. In contrast, the ε2 allele has been associated
with a ~ 50% reduction in AD risk compared to the ε3/
ε3 genotype [5].
The three APOE alleles (ε2/ε3/ε4) are defined by two
APOE exon 4 single-nucleotide polymorphisms (SNPs)
and encode functionally distinct ApoE isoforms.
Isoform-dependent behaviours have been observed for
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many ApoE functions, including lipid metabolism, amyl-
oid beta (Aβ) metabolism, tau phosphorylation, inflam-
mation and synaptic plasticity, with ApoE4 and ApoE2
conferring effects consistent with increased and reduced
AD risk, respectively [6, 7].
Despite the wealth of evidence linking ApoE to pro-
cesses implicated in AD pathogenesis, understanding of
the specific mechanism(s) by which genetic variation at
this locus alters risk remains incomplete. APOE geno-
type acts in conjunction with other genetic and/or envir-
onmental factors to confer AD risk: the lifetime risk of
dementia or mild cognitive impairment is 31%–40% for
ε4/ε4 homozygotes [8] but the effects of APOE ε4 have
been shown to be modified by ethnic background and
sex [5, 9]. DNA methylation is associated with both gen-
etic and environmental factors, and previous studies
have identified associations with AD and neuropatho-
logical hallmarks of AD [10–12], AD risk factors (e.g.
ageing [13], obesity [14] and lipid levels [15]), as well as
modifiers of APOE genotype effects (e.g. sex [16] and
ethnicity [17, 18]).
The two APOE haplotype-defining SNPs are located in
a CpG island and have a direct effect on methylation by
creating/destroying CpG sites [19]. The APOE ε2/ε3/ε4
haplotype is associated with methylation at other CpG
sites within APOE [20, 21] but, to date, associations with
methylation across the epigenome have not been
assessed. We hypothesised that characterising these as-
sociations would yield insights into the biological con-
text in which APOE acts, thus facilitating the search for
mechanisms conferring risk/resilience for AD. Import-
antly, by studying individuals who are free from AD, we
have the potential to identify pathogenic processes that
precede the onset of irreversible neurodegeneration.
Methods
Participants
The participants were selected from the Generation
Scotland: Scottish Family Health Study (GS:SFHS) co-
hort (~ 24,000 participants aged ≥ 18 years at recruit-
ment), which has been described previously [22, 23].
The participants included in this study were of European
(predominantly British) ancestry, following the exclusion
of participants with likely recent Italian or African/Asian
ancestry by principal components (PC) analysis [24].
Participants attended a baseline clinical appointment at
which they were phenotyped for social, demographic,
health and lifestyle factors, completed cognitive assess-
ments and provided physical measurements and samples
for DNA extraction. GS:SFHS obtained ethical approval
from the NHS Tayside Committee on Medical Research
Ethics, on behalf of the National Health Service (refer-
ence: 05/S1401/89) and has Research Tissue Bank Status
(reference: 15/ES/0040).
Blood sample collection and DNA extraction
DNA was extracted from blood (9 ml) collected in
EDTA tubes using the Nucleon BACC3 Genomic DNA
Extraction Kit (Fisher Scientific), following the manufac-
turer’s instructions [25].
Genotyping of APOE
The APOE ε2/ε3/ε4 haplotypes are defined by two SNPs,
rs429358 and rs7412, which were genotyped using Taq-
Man probes at the Clinical Research Facility, Edinburgh.
Measurement of cholesterol levels
Total and high-density lipoprotein (HDL) cholesterol
were measured at the GS:SFHS baseline appointment
and non-HDL cholesterol levels were calculated by sub-
tracting HDL cholesterol from total cholesterol. The
non-HDL cholesterol level reflects a combination of
low-density lipoprotein (LDL) cholesterol and very low-
density lipoprotein.
Genome-wide DNA methylation profiling for EWAS
analyses
DNA methylation was profiled using the Infinium
MethylationEPIC BeadChip (Illumina Inc.) in a discovery
(n = 5190) and replication (n = 4583) sample, as de-
scribed previously [26–28] (Supplementary Methods).
The discovery and replication samples were normalised
separately and converted to M values. The discovery
data was corrected for relatedness (Supplementary
Methods). Participants in the replication sample were
unrelated (SNP-based relatedness< 0.05) to each other
and/or discovery sample participants.
Poor performing probes, X/Y chromosome probes and
participants with unreliable self-report data or potential
XXY genotype were excluded (Supplementary Methods).
The final discovery dataset comprised M values at 760,
943 loci for 5087 participants; the replication dataset
comprised M values at 758,332 loci for 4450 partici-
pants. All subsequent analyses of the DNA methylation
data were carried out using R versions 3.6.0., 3.6.1., or
3.6.2 [29, 30].
Statistical analyses
A flow chart indicating all analyses is presented in Fig. 1.
Epigenome-wide association studies
EWASs were implemented using limma [31]. CpG M
values were the dependent variable and APOE ε4 vs. ε2
carrier status (a binary variable indicating APOE ε4 car-
riers with a “1” and APOE ε2 with a “0”; ε4/ε2 and ε3/ε3
participants were excluded) was the predictor-of-
interest. Participants self-reporting AD (n = five) were
excluded. Additional covariates were included as below:
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Discovery sample
CpG site (pre-corrected for relatedness, estimated cell
counts and processing batch) ~ APOE ε4 vs. ε2 + age +
sex + smoking status + pack years + 20 methylation PCs
Replication sample
CpG site (M values) ~ APOE ε4 vs. ε2 + age + sex +
smoking status + pack years + estimated cell counts
(granulocytes, natural killer cells, B lymphocytes, CD4 +
T lymphocytes and CD8 + T lymphocytes) + processing
batch + 20 methylation PCs
The variables “smoking status”, “pack years” and the
methylation PCs are explained in the Supplementary
Methods.
An additional sensitivity analysis of the replication
sample was performed in which the first 10 genetic PCs,
calculated using GCTA [32], were included. The deci-
sion to include 10 PCs was based on inspection of a
scree plot (Additional file 2: Fig. S1).
Limma was used to calculate empirical Bayes moder-
ated t-statistics from which P values were obtained. The
significance threshold in the discovery sample was P ≤
3.6 × 10−8 [33]. Sites attaining significance in the discov-
ery sample were assessed in the replication sample using
a Bonferroni-corrected threshold of 0.05/no. sites
assessed.
EWAS meta-analysis
Inverse variance-weighted fixed effects meta-analyses of
756,971 sites common to the discovery and replication
EWAS results were performed using METAL [34]. Sites
attaining a meta-analysis P ≤ 3.6 × 10−8 were considered
significant.
Comparison of DNA methylation levels between APOE
haplotypes
For the differentially methylated positions (DMPs) iden-
tified through the EWAS meta-analysis, pairwise differ-
ences in methylation levels between carriers of the
APOE ε2/ε2, ε2/ε3, ε3/ε3, ε3/ε4 and ε4/ε4 haplotypes in
the discovery sample were investigated, using the R
package lsmeans [35]. P values were adjusted using a
Bonferroni correction to account for the 10 within-CpG
comparisons performed for each of the 20 CpGs
Fig. 1 Flow chart indicating the analyses carried out in this study. Yellow boxes indicate datasets used for the analysis, blue boxes describe the
analysis performed and green boxes contain the results of the analysis. Arrows indicate the analyses for which the datasets were used, the order
of the analyses and the results from each analysis
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assessed (i.e. an adjustment was performed for 200 tests).
Corrected P ≤ 0.05 was considered statistically
significant.
Identification of differentially methylated regions
DMRs associated with APOE ε4 vs. ε2 carrier status were
identified using the dmrff.meta function from the dmrff
R package [36]. Putative DMRs were defined as regions
containing two to thirty sites separated by ≤ 500 bp with
EWAS meta-analysis P ≤ .05 and methylation changes in
a consistent direction. Following dmrff’s subregion selec-
tion step, DMRs with Bonferroni-adjusted P ≤ .05 were
declared significant.
Gene ontology/KEGG pathway analyses
Gene ontology (GO) and KEGG pathway analyses were
implemented using missMethyl’s gometh function [37].
The target list comprised probes that were suggestively as-
sociated with the phenotype-of-interest (P ≤ 1 × 10−5) in
the meta-EWAS or that contributed to a significant DMR
(adjusted P ≤ 0.05) and the gene universe included all ana-
lysed probes. Enrichment was assessed using a hypergeo-
metric test, accounting for the bias arising from the
variation in the number of probes-per-gene. Bonferroni-
corrected significance thresholds of P ≤ 2.21 × 10−6 and
P ≤ 1.48 × 10−4 were applied to account for the 22,578 GO
terms and 337 KEGG pathways assessed.
Bootstrap mediation analysis
The roles of cholesterol levels (total cholesterol, HDL
cholesterol and non-HDL cholesterol) in mediating any
observed associations between APOE ε4 vs. ε2 carrier sta-
tus and DNA methylation were assessed by bootstrap me-
diation analysis using the R package “mediation” [38]. The
analyses were performed using 10,000 bootstrap samples
in the discovery and replication samples separately and
these results were then meta-analysed using inverse
variance-weighted fixed effects meta-analyses to obtain
meta-analyses P values and effect estimates. Significant
mediation was declared when the meta-analysis P value
met a Bonferroni-adjusted (to account for the assessment
of 20 DMPs) significance threshold of P ≤ .05.
Genotyping and imputation
The genotyping and imputation of GS:SFHS to the Haplo-
type Reference Consortium reference panel release 1.1 [39]
has been described previously [25, 40] (Supplementary
Methods).
Identification of methylation quantitative trait loci
Methylation quantitative trait loci (meQTLs) were iden-
tified using the discovery sample. Following quality con-
trol, the data was normalised and corrected as described
previously [41] (Supplementary Methods). Normalised
and corrected data was available for 26 of the 31 CpGs-
of-interest in this study. The resulting residuals were in-
verse rank normal transformed and entered as the
dependent variable in simple linear model GWASs to
identify meQTLs. GWASs were implemented using
REGSCAN v0.5 [42]. SNPs that were associated with a
CpG with P ≤ 1.92 × 10−9 (5 × 10−8/26) were declared to
be meQTLs. SNPs located within one megabase up- or
downstream of their associated CpG were defined as cis
meQTLs; all other associated SNPs were defined as trans
meQTLs. A look-up analysis of the GWAS catalog [43]
(GWAS catalog v1.0.2., downloaded 07/09/20) was per-
formed in which SNPs identified as meQTLs for the
CpGs of interest were queried for their significant (P ≤
5 × 10−8) disease or trait associations in the GWAS
catalog.
Association analyses of APOE ε4 vs. ε2 carrier status
Association analyses were performed to assess whether
meQTLs for the meta-analysis DMPs are associated with
APOE ε4 vs. ε2 carrier status and, therefore, might con-
tribute to the differences in methylation observed be-
tween APOE ε4 and ε2 carriers. Association tests used
BOLT-LMM [44] to perform linear mixed models in
participants with available APOE genotypes (ε2 n = 2613;
ε4 n = 5401). BOLT-LMM adjusts for population struc-
ture and relatedness between individuals whilst assessing
association. Sex was included as a covariate. Associations
were considered significant when P ≤ 5 × 10−8.
Results
Sample demographics
The EWAS discovery sample comprised 1253 APOE ε4
and 596 APOE ε2 allele carriers and the replication sam-
ple comprised 1216 APOE ε4 and 522 APOE ε2 allele
carriers. Twenty-seven ε2/ε2, 569 ε2/ε3, 2926 ε3/ε3,
1128 ε3/ε4 and 125 ε4/ε4 participants from the discov-
ery sample were available for the pairwise analysis of ge-
notypes. Key sample demographic information is
presented in Additional file 1: Table S1.
Identification of differentially methylated positions and
regions in APOE ε4 vs. ε2 carriers
An EWAS of APOE ε4 vs. ε2 carriers in the discovery sam-
ple identified eight significant DMPs, of which half were
hypermethylated in APOE ε4 carriers. These DMPs had a
mean absolute effect size of 0.070 (range 0.033–0.103) and
P values ranging from 6.40 × 10−56 to 8.81 × 10−9. All eight
sites were also significant (8.60 × 10−49 ≤ P ≤ 7.25 × 10−6) in
the replication sample with a consistent direction of effect
(mean absolute effect size = 0.102; range 0.049–0.170;
Additional file 1: Table S2). The eight sites are located in a
~ 169 kb region on chromosome 19 (chr. 19: 45,242,346-45,
411,802; GRCh37/hg19), which spans a region of the
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genome upstream of and including part of the APOE gene
(chr19: 45,409,039–45,412,650; GRCh37/hg19). A sensitiv-
ity analysis of the discovery sample in which a methylation-
based smoking score [45] was included as a covariate
instead of the smoking covariates included in the original
analysis (“smoking status” and “pack years”) produced
highly similar results across all measured CpGs (correlation
between effect sizes = 0.99, 95% confidence interval (CI)
0.99–0.99; P < 2.2 × 10−16; Additional file 1: Table S2). An
additional sensitivity analysis in which the first 10 genetic
PCs were included as additional covariates in the analysis of
the replication sample also produced results that were
highly correlated with those from the original replication
sample analysis (r = 1.00, 95% CI 1.00–1.00, P < 2.2 × 10−16;
Additional file 1: Table S2).
Inverse variance-weighted fixed effects meta-analysis
of the discovery and replication samples identified 20
DMPs, with APOE ε4 carrier status associated with hy-
pomethylation at 13 (65%) of these sites. Across all 20
DMPs, the mean absolute effect size was 0.052 (range
0.022–0.11) with P values ranging from 2.80 × 10−100 to
2.4 × 10−8 (Table 1; Fig. 2). Sixteen of these sites are lo-
cated on chromosome 19q in a ~ 233 kb region (chr19:
45,221,584–45,454,752; GRCh37/hg19) encompassing
APOE and several surrounding genes (Additional file 2:
Fig. S2). Henceforth, the region containing APOE and
neighbouring genes will be referred to as the “APOE
locus”. The most significant DMP, cg13375295, is lo-
cated ~ 4.5 kb upstream of poliovirus receptor-related 2
(PVRL2), a gene situated ~ 16.5 kb upstream of APOE.
Four other DMPs (cg10762466, cg10178308, cg11643040
and cg06198803) are located either upstream or in the
gene body of PVRL2. Two DMPs (cg06750524 and
cg16471933) are located in APOE: cg06750524, the
DMP with the largest effect size, in the intron between
exons 2 and 3, and cg16471933 in exon 4, 139 bp 5′ of
rs429358, one of the APOE ε4/ε2-defining SNPs. Al-
though both the APOE DMPs are more highly methyl-
ated in APOE ε4 carriers; the DMPs in the surrounding
region do not show a consistent direction of effect.
Four DMPs are located outside of chromosome 19q:
cg17901584, 785 bp upstream of the 24-dehydrocholes-
terol reductase (DHCR24) gene on chromosome 1;
cg19751789, 94 bp upstream of the low-density lipopro-
tein receptor (LDLR) gene on chromosome 19p; and two,
cg16740586 and cg06500161, are located 668 bp apart in
the same intron of multiple ATP binding cassette sub-
family G member 1 (ABCG1) isoforms.
Table 1 APOE ε4 vs. ε2-associated DMPs identified by meta-analysis of the discovery and replication EWASs
Probe ID Gene symbol Gene feature* Chr. BP† Effect‡ SE P value
cg13375295 19 45344725 − 0.1031 0.0049 2.80 × 10−100
cg06750524 APOE Body 19 45409955 0.1122 0.008 1.05 × 10−44
cg16094954 BCL3 TSS1500 19 45251180 − 0.0994 0.0081 8.18 × 10−35
cg10762466 19 45347693 − 0.0463 0.004 1.37 × 10−30
cg16471933 APOE Body 19 45411802 0.0606 0.0055 7.17 × 10−28
cg10178308 PVRL2 TSS200 19 45349383 0.1075 0.0103 2.04 × 10−25
cg27087650 BCL3 Body 19 45255796 0.0455 0.0044 3.77 × 10−25
cg04488858 19 45242346 − 0.0514 0.0065 2.25 × 10−15
cg11643040 PVRL2 Body 19 45361327 − 0.0278 0.0038 1.46 × 10−13
cg26631131 19 45240591 0.0298 0.0042 2.45 × 10−12
cg17901584 DHCR24;RP11-67 L3.4 TSS1500 1 55353706 − 0.0403 0.0058 3.58 × 10−12
cg06198803 PVRL2 Body 19 45371896 − 0.041 0.006 1.04 × 10−11
cg16740586 ABCG1 Body 21 43655919 0.0332 0.005 3.58 × 10−11
cg03793277 APOC1 TSS1500 19 45416910 − 0.0304 0.0049 5.99 × 10−10
cg06500161 ABCG1 Body 21 43656587 0.0247 0.0042 2.67 × 10−9
cg09555818 APOC2;APOC4 5′ UTR; 1st exon 19 45449301 − 0.0531 0.0091 5.77 × 10−9
cg13119609 APOC2;APOC4 5′ UTR; 1st exon 19 45449297 − 0.0464 0.008 5.84 × 10−9
cg15233575 19 45221584 − 0.0223 0.0039 7.17 × 10−9
cg14645843 19 45454752 − 0.0346 0.0062 2.31 × 10−8
cg19751789 LDLR 19 11199944 − 0.0338 0.0061 2.43 × 10−8
Abbreviations: BP base position, Chr. chromosome, SE standard error, TSS transcription start site, UTR untranslated region
*Gene feature: 5′ UTR between the TSS and the ATG, Body between the ATG and the stop codon, TSS200 within 200 bases 5′ of the TSS, TSS1500 within 1500
bases 5′ of the TSS
†Base position in genome assembly hg19/GRCh37
‡Effect direction is relative to carriers of the ε2 allele
Walker et al. Genome Medicine            (2021) 13:1 Page 5 of 14
To further investigate the pattern of methylation ob-
served at these 20 DMPs, pairwise comparisons were
performed between carriers of the following APOE hap-
lotypes: ε2/ε2, ε2/ε3, ε3/ε3, ε3/ε4 and ε4/ε4. These ana-
lyses revealed a range of allele-associated methylation
patterns, which are depicted in Additional file 2: Fig. S3
and described in Additional file 1: Table S3. Carriers of
the APOE ε2 allele (ε2/ε2 or ε2/ε3) differed from ε3/ε3
homozygotes at 14 of the DMPs, whilst carriers of the
APOE ε4 allele (ε4/ε4 or ε3/ε4) differed from ε3/ε3 ho-
mozygotes at four DMPs. Dosage effects were observed
at two DMPs for ε2 carriers (Additional file 2: Fig. S3A
and S) and one DMP for ε4 carriers (Additional file 2:
Fig. S3B), although the small numbers of participants
who are homozygous for APOE ε2 (n = 27) and ε4 (n =
128) likely rendered our study underpowered to detect
all dosage effects. For the two DMPs located within the
APOE gene (cg06750524 and cg16471933), an increase
in mean methylation levels was observed from ε2/ε2 ho-
mozygotes to ε3/ε3 homozygotes, with a further increase
to the ε4/ε4 group (Additional file 2: Fig. S3B and E). At
the four DMPs outside of the APOE locus, the methyla-
tion differences appear to be predominantly driven by
the ε2 allele (Additional file 2: Fig. S3K, M, O and S).
Differentially methylated regions (DMRs) were identi-
fied using a meta-analysis approach, which identified six
significant regions (Additional file 2: Fig. S4). Across all
the DMRs, the mean absolute effect size was 0.182
(range 0.135–0.231) and Bonferroni-adjusted P values
ranged from 1.63 × 10−4 to 3.01 × 10−2 (Table 2).Three of
the DMRs are located at the APOE locus, two are in the
first intron of sterol regulatory element binding tran-
scription factor 2 (SREBF2) on chromosome 22, and the
other is in the putative promoter of LDLR on chromo-
some 19p. All but one of the DMRs, which is located
190 bp upstream of the apolipoprotein C1 pseudogene 1
(APOC1P1) at the APOE locus, are hypomethylated in
APOE ε4 carriers. Only one of the DMRs, located in an
exon of a read-through transcript involving apolipopro-
tein C2 (APOC2) and apolipoprotein C4 (APOC4), con-
tains CpGs that were identified as DMPs (cg13119609
and cg09555818).
GO analysis was carried out using the 19 Entrez IDs
mapping to the 46 CpG sites with a meta-EWAS P ≤ 1 ×
10−5 or that contributed to a significant DMR. This
identified 78 significant GO terms (Table 3; Additional
file 1: Table S4), the most significant of which was “chol-
esterol metabolic process” (P = 2.00 × 10−11). Significant
enrichment for the KEGG pathways “cholesterol metab-
olism” (P = 5.93 × 10−10) and “steroid biosynthesis” (P =
1.22 × 10−4) was also observed.
Assessment of the role of cholesterol in mediating
methylation differences between APOE ε4 and ε2 carriers
Given the well-established role of ApoE in cholesterol
metabolism [6], bootstrap mediation analyses were per-
formed to assess the role of cholesterol levels (total,
HDL or non-HDL cholesterol) in mediating the associ-
ation between APOE ε4 vs. ε2 carrier status and methy-
lation at the 20 meta-analysis DMPs. Inverse variance-
weighted fixed effects meta-analysis of the bootstrap me-
diation analyses in the discovery and replication samples
identified HDL cholesterol as a significant mediator of
the associations with the two ABCG1 DMPs cg06500161
(effect size = 0.006; effect size standard error = 0.001; P =
1.18 × 10−6) and cg16740586 (effect size = 0.004; effect
size standard error = 0.001; P = 4.93 × 10−5), and the
DHCR24 promoter DMP, cg17901584 (effect size = −
0.007; effect size standard error = 0.001; P = 6.04 × 10−6),
for which it mediated 25.2%, 11.5%, and 18.2% of the re-
lationship, respectively (Additional file 1: Table S5). For
some sites, inspection of the P values indicated total and
Fig. 2 Manhattan plot showing the APOE ε4 vs. ε2 carrier EWAS and DMR meta-analyses results. Each point represents one of the 772,453 loci
included in the EWAS meta-analysis, with the point’s position being determined by genomic position (x-axis) and significance in the EWAS meta-
analysis (−log10 P value; y-axis). Sites attaining genome-wide significance (P ≤ 3.6 × 10
−8) are indicated in red and those that are involved in a
significant DMR (Bonferroni-correct P ≤ 0.05) are indicated in blue. The locations of DMRs are further indicated by vertical blue lines. The solid
horizontal line is the threshold for genome-wide significance (P ≤ 3.6 × 10−8)
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non-HDL cholesterol to be significant mediators but the
proportion of the relationship between APOE ε4 vs. ε2
carrier status and methylation attributable to the medi-
ator was negative (Additional file 1: Table S5). This indi-
cates that, at these sites, the direction of the association
between the cholesterol phenotypes and methylation is
the opposite to the direction of the association between
APOE ε4 vs. ε2 carrier status and methylation.
Assessment of meQTLs associated with loci that are
differentially methylated between APOE ε4 and ε2 carriers
To explore the DMP and DMR CpGs further, meQTL
analyses were performed. Whilst it was expected that
meQTLs for the DMP and DMR CpGs would be identi-
fied at the APOE locus, the identification of meQTLs
outside of this locus would be of particular interest.
Should meQTLs outside of the APOE locus be found to
be show non-random segregation with APOE ε4 vs. ε2
carrier status, these meQTL SNPs might contribute to
the methylation differences observed in this study and
APOE genotype effects more generally.
It was possible to assess meQTLs for 26 of the 31
CpGs of interest (from the DMP and DMR analyses);
amongst these CpGs, 23 were associated with a meQTL.
In total, 3727 significant CpG-SNP associations were
identified for the 23 CpGs, involving 1654 unique SNPs
(Fig. 3; Additional file 1: Table S6). Unsurprisingly, more
than half of the meQTLs (n = 947) were located in a ~
719 kb region (chr19: 45,004,645–45,723,446; GRCh37/
hg19) spanning APOE. The APOE region meQTLs are
associated with 16 CpGs, of which 14 are located at the
APOE locus. None of these meQTLs is associated with
all 16 CpGs: two are each associated with nine CpGs:
rs7412, one of the APOE ε2/ε3/ε4-defining SNPs; and
rs41290120, an intronic PVRL2 SNP that is in high link-
age disequilibrium with rs7412 with D’ = 0.85 in the Brit-
ish population [46]. The two CpGs associated in trans
with SNPs in the APOE region are cg16000331 in
SREBF2 and cg19751789 in LDLR.
Outside of the APOE locus, the remaining 707
meQTLs, which are associated with 10 CpGs, are located
in 11 genomic regions (Fig. 3; Additional file 1: Table
S7), with each region containing meQTLs associated
with between one and eight CpGs-of-interest. To assess
whether these meQTLs might contribute to APOE ε4 vs.
ε2-associated methylation differences, their association
with APOE ε4 vs. ε2 carrier status was assessed. No sig-
nificant associations were observed, suggesting that the
APOE ε4 vs. ε2-associated methylation differences are
predominantly driven by genotype at the APOE locus.
To investigate potential trait/disease associations with
variation in methylation levels at the CpGs-of-interest,
the GWAS catalog was queried [43]. This identified 234/
1654 meQTLs as having genome-wide significant associ-
ations with 316 traits (Additional file 1: Table S8). More
than one third of the associations are with a lipid-related
traits, including LDL, HDL and total cholesterol levels.
As expected, many of the meQTL SNPs within the
APOE locus have previously been associated with AD
and related traits, such as “cerebrospinal fluid p-tau
levels”, “cerebral amyloid deposition (PET imaging)” and
“cognitive decline”. Interestingly, five SNPs located out-
side of the APOE locus have also been associated with
traits related cognitive ability (“cognitive ability, years of
educational attainment or schizophrenia (pleiotropy)”,
“general cognitive ability”, “intelligence” and “self-re-
ported math ability”). Four of these SNPs encompass the
3′ end of CCDC134 and most of the neighbouring
SREBF2. Between them, these four SNPs are associated
in cis with methylation at the four CpGs forming the
two SREBF2 DMRs. The fifth SNP, which is located on
chromosome 6 in the pseudogene CCDC162P, is associ-
ated with methylation at CpGs in SREBF2 and LDLR.
Three meQTL SNPs have been associated with several
age-related disorders (e.g. heart failure, stroke, and can-
cer) and endophenotypes of these disorders (including
cholesterol levels, blood pressure and blood glucose) in a
pleiotropic GWAS meta-analysis [47].
Discussion
We performed the first epigenome-wide comparison of
DNA methylation between carriers of the APOE ε4 and
Table 2 Significant DMRs identified through DMR meta-analysis of the discovery and replication sample EWAS results
Chr. Coordinates* Gene symbol Effect† SE Adj. P value‡ CpGs
19 45,449,297–45,449,301 APOC2; APOC4 − 0.231 0.0364 1.63 × 10−4 cg13119609; cg09555818
19 45,449,099–45,449,150 APOC4-APOC2; APOC2; APOC4 − 0.212 0.0356 0.00203 cg01958934; cg10872931
19 11,199,851–11,199,903 LDLR − 0.135 0.0245 0.0290 cg07960944; cg05249393; cg22381454;
22 42,230,879–42,230,899 SREBF2 − 0.189 0.0329 0.00755 cg15128785; cg12403973
22 42,229,983–42,230,138 SREBF2 − 0.176 0.0312 0.0118 cg09978077; cg16000331
19 45,429,771–45,429,870 APOC1P1 0.148 0.0269 0.0301 cg23184690; cg08121984
Abbreviations: Chr. chromosome, SE standard error, Adj. adjusted, CpGs cytosine and guanine nucleotides linked by a phosphate bond
*DMR start and end coordinates in genome assembly hg19/GRCh37
†Effect direction is relative to carriers of the ε2 allele
‡Bonferroni-adjusted P value
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ε2 haplotypes, which confer risk for and protection from
AD, respectively. In large discovery and replication sam-
ples, we confirm the presence of APOE haplotype-
associated methylation differences in APOE, demon-
strate that differences in methylation at the APOE locus
span a broad genomic locus encompassing several genes
and find evidence for altered methylation at sites un-
linked to the APOE locus. The observed methylation dif-
ferences are located in a network of genes involved in
lipid metabolism and homeostasis.
Methylation differences were identified using discov-
ery, replication and meta-analysis EWASs and DMR
analysis. Eight DMPs located on chromosome 19 in a ~
169 kb region spanning from upstream of BCL3 to the
APOE’s fourth exon showed replicated association. An
additional twelve DMPs, eight of which are located in a
~ 233 kb region at the APOE locus, were identified by
meta-analysing the discovery and replication samples.
DMR analysis identified six regions of differential methy-
lation, both within and outside of the APOE locus.
Within the APOE gene, two DMPs, cg06750524, in the
second intron, and cg16471933, in the fourth exon, were
identified. APOE ε4 carriers showed higher methylation
levels at both. This observation directly replicates a pre-
vious study [21] and is in line with Foraker et al.’s obser-
vation of increased methylation of the APOE exon 4
CpG island in ε4 carriers [20]. Moreover, we have previ-
ously demonstrated [48] that the pattern of methylation
in APOE in our sample is consistent with that described
by Ma et al. [21]. Pairwise comparisons revealed differ-
ences in APOE methylation to be driven both by differ-
ences between ε2 carriers and ε3/ε3 homozygotes and ε4
Table 3 Top 20 GO terms showing significant enrichment for APOE ε4 vs. ε2-associated differentially methylated loci
Ontology category Term Proportion* P value Genes
BP Cholesterol metabolic
process
7/146 2.00 × 10−11 DHCR24, APOC1, APOE, LDLR, SQLE, SREBF2, ABCG1
BP Secondary alcohol
metabolic process
7/156 3.59 × 10−11 DHCR24, APOC1, APOE, LDLR, SQLE, SREBF2, ABCG1
BP Chylomicron remnant
clearance




4/9 4.29 × 10−11 APOC1, APOC2, APOE, LDLR
BP Sterol metabolic process 7/162 4.78 × 10−11 DHCR24, APOC1, APOE, LDLR, SQLE, SREBF2, ABCG1
BP Cholesterol homeostasis 6/94 7.57 × 10−11 MYLIP, APOC2, APOE, LDLR, SREBF2, ABCG1
BP Sterol homeostasis 6/94 7.57 × 10−11 MYLIP, APOC2, APOE, LDLR, SREBF2, ABCG1
BP Cholesterol transport 6/98 1.04 × 10−10 APOC1, APOC2, APOE, LDLR, SREBF2, ABCG1
BP Regulation of plasma
lipoprotein particle levels
6/100 1.17 × 10−10 MYLIP, APOC1, APOC2, APOE, LDLR, ABCG1
BP Phospholipid transport 6/90 1.27 × 10−10 APOC1, APOC2, APOE, KCNN4, LDLR, ABCG1
BP Regulation of lipid
biosynthetic process
7/190 1.50 × 10−10 APOC1, APOC2, APOE, LDLR, SQLE, SREBF2, ABCG1
BP Phospholipid efflux 4/12 1.50 × 10−10 APOC1, APOC2, APOE, ABCG1
BP Sterol transport 6/111 2.65 × 10−10 APOC1, APOC2, APOE, LDLR, SREBF2, ABCG1
BP Cholesterol efflux 5/56 4.60 × 10−10 APOC1, APOC2, APOE, SREBF2, ABCG1
BP Organophosphate
ester transport
6/116 6.18 × 10−10 APOC1, APOC2, APOE, KCNN4, LDLR, ABCG1
BP Regulation of
cholesterol transport
5/61 6.55 × 10−10 APOC1, APOC2, APOE, SREBF2, ABCG1
BP Regulation of steroid
metabolic process
6/123 6.67 × 10−10 APOC1, APOE, LDLR, SQLE, SREBF2, ABCG1
BP Regulation of sterol
transport
5/62 7.34 × 10−10 APOC1, APOC2, APOE, SREBF2, ABCG1
BP Lipid localization 8/407 7.54 × 10−10 APOC1, APOC2, APOE, KCNN4, LDLR, SQLE, SREBF2, ABCG1
BP High-density lipoprotein
particle remodeling
4/18 1.14 × 10−9 APOC1, APOC2, APOE, ABCG1
Abbreviations: BP biological process, GO gene ontology
*Number of significant target list-associated Entrez IDs associated with the gene ontology term/total number of Entrez IDs associated with the GO term. The
target list comprised probes that met a nominal threshold for association with APOE ε4 vs. ε2 carrier status of P ≤ 1 × 10−5
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carriers and ε3/ε3 homozygotes. One interpretation of
this observation is that the spectrum of methylation at
the APOE DMPs reflects the spectrum of AD risk con-
ferred by different AD genotypes. It is clear, however,
that additional, likely experimental, studies are required
to assess the implications of the observed methylation
pattern.
The differentially methylated CpGs at the APOE locus
span a broad region that encompasses several genes con-
taining AD-associated variants [49]. Long-ranging link-
age disequilibrium in the region complicates the
interpretation of association signals; however, condi-
tional analysis and fine-mapping studies suggest the
presence of multiple independent AD risk loci across the
region [3, 49]. As such, the methylation differences ob-
served in this study may be associated with variants that,
whilst being in LD with the APOE ε2/ε4-defining SNPs,
confer risk via different pathways to these SNPs. This
notion is supported by the observation that SNPs that
define an APOE ε4-independent AD-risk haplotype in
PVRL2 [49] are highly significant meQTLs for the most
significant DMP identified in this study.
Beyond the APOE locus, DMPs were identified in an
ABCG1 intron, and upstream of DHCR24 and LDLR.
Comparisons with ε3/ε3 homozygotes suggested the ε2
allele to be the primary driver of these differences, sug-
gesting the possibility that altered methylation of genes
involved in lipid metabolism might contribute to this al-
lele’s protective effects. DMRs were identified in the
gene body of SREBF2 and in the putative promoter re-
gion of LDLR. The CpGs involved in the DMPs and
DMRs located outside of the APOE locus are associated
with several meQTLs, with all of the CpGs except those
involved in the LDLR DMR being associated with
meQTLs in cis as well as in trans. Our findings did not,
however, support a role for cis meQTLs for these CpGs
driving associations with APOE ε4 vs. ε2 carrier status.
The genes outside of the APOE locus that harbour dif-
ferentially methylated CpGs are implicated in lipid me-
tabolism or homeostasis. ABCG1, which is highly
Fig. 3 Circular plot indicating the locations of APOE ε4 vs. ε2 carrier-associated DMP and DMR CpGs. The first track shows a chromosome
ideogram (hg19/GRCh37). The genomic locations of CpGs identified as being DMPs or in DMRs identified in APOE ε4 vs. ε2 carriers are indicated
by blue lines on the second track and the meQTLs associated with these CpGs are indicated by the red lines on the third track. The connections
between CpGs and meQTLs indicate regulatory relationships (cis interactions in red; trans interactions in blue). Gene symbols for genes located in
each CpG/meQTL-harbouring region are indicated
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expressed in the brain, encodes a cholesterol and
phospholipid transporter and is involved in regulating
the sterol biosynthetic pathway [50]. DHCR24, which en-
codes the cholesterol biosynthesis enzyme 3ß-hydroxys-
terol-Δ24 reductase, also known as seladin-1, plays a
neuroprotective role in AD-related stress conditions, in-
cluding Aβ toxicity, oxidative stress and inflammation
[51, 52]. The alteration of seladin-1 expression in mouse
brain and human neuroblastoma cell cultures has been
shown to affect β-secretase processing of amyloid pre-
cursor protein, with reduced seladin-1 being associated
with an increased rate of Aβ production [53]. Future
studies should assess whether methylation-associated
differences in the brain expression of seladin-1 [6] might
mediate the established associations between APOE ε4
vs. ε2 haplotype and Aβ production. The LDLR gene en-
codes the LDL receptor, one of the neuronal receptors
capable of mediating the endocytosis of ApoE, thus
maintaining brain cholesterol homeostasis. LDLR expres-
sion is regulated, in part, by SREBF2, a transcriptional
regulator of sterol-regulated genes, which contains a
SNP that is associated both with SREBF2 expression and
CSF levels of the AD biomarkers Aβ and tau [54].
The link between APOE ε4 vs. ε2-associated methyla-
tion differences and lipid-related processes and pathways
was further supported by GO and KEGG analyses, the
identification of meQTLs for the differentially methyl-
ated CpGs, which were clustered in genomic regions
that contain several lipid-related genes, and their
GWAS-associated phenotypes. It would be of interest to
investigate the mechanisms underlying the clustering of
meQTLs in these genomic regions. Future studies might
assess, for example, the extent to which meQTLs associ-
ated with the differentially methylated CpGs are
enriched in these regions and whether they dispropor-
tionately affect certain sequence motifs. Previous EWASs
have also identified associations between some of the
APOE ε4 vs. ε2-associated CpGs and cholesterol levels:
the DHCR24 (cg17901584), ABCG1 (cg06500161) and
SREBF2 (cg16000331) DMPs have been associated with
HDL cholesterol, total cholesterol and triglyceride levels
[15, 55–57]. Comparisons with previous EWASs are,
however, limited by the fact that the majority of previous
EWASs used the 450 K array, which does not contain 10
of the APOE ε4 vs. ε2-associated CpGs.
As differences in lipid metabolism between carriers of
the APOE ε4 and ε2 haplotypes are well-documented
[6], we assessed whether variation in blood cholesterol
levels might mediate the observed APOE ε4 vs. ε2-
associated methylation differences. HDL cholesterol was
found to be a partial mediator of the relationship be-
tween APOE ε4 vs. ε2 carrier status and methylation at
three loci located outside of the APOE locus (two within
ABCG1 and one in the promoter of DHCR24), thus
suggesting one mechanism that might underlie these
trans effects. Consistent with our observation that
methylation differences at these loci appear to be pre-
dominantly driven by APOE ε2 carriers (when compared
to APOE ε3/ε3 homozygotes), higher HDL cholesterol
levels have been reported in carriers of APOE ε2 [58].
The effect of HDL cholesterol on methylation varied be-
tween the three loci, with APOE ε2 carriers showing in-
creased methylation at the site located in the DHCR24
promoter and decreased methylation at the two ABCG1
sites. This suggests that increased HDL cholesterol levels
do not exert a general effect on methylation but rather
that methylation varies in a locus-specific manner in re-
sponse to variation in HDL levels. It should be noted
that an assumption of this analysis is that reverse caus-
ation does not exist between the outcome, methylation,
and the mediator, cholesterol. Previous Mendelian ran-
domisation studies have predominantly supported this
premise [59, 60]; however, the ability to identify robust
genetic instruments has limited both the number of
methylation sites assessed and the ability to assess re-
verse causation. Limitations to the GS:SFHS cholesterol
data should also be noted when interpreting these find-
ings: triglyceride levels were not measured, preventing
LDL cholesterol assessment, and blood samples were
not taken at a consistent time of day or after fasting.
The cross-sectional nature of this study precludes the
observed methylation differences being interpreted as
conferring risk, protection or compensation. Compari-
son of methylation at these loci in APOE ε4 and ε2 car-
riers with AD would be useful in addressing this
question; however, the optimum study design would in-
volve the longitudinal assessment of the trajectory of ε4
vs. ε2-associated methylation differences in AD-free in-
dividuals in midlife who either do or do not later de-
velop AD. These analyses are currently not feasible due
to the small sizes of existing AD patient blood-based
DNA methylation samples and insufficient follow-up
time of large population-based samples.
Studies assessing the association of neuropathological
hallmarks (neuritic plaque burden and/or neurofibrillary
tangles) of AD with DNA methylation in the brain have
not identified the loci identified in the present study [10,
12, 61]. Although the phenotypes assessed differ, the ex-
istence of APOE haplotype-associated differences in Aβ
metabolism and tau phosphorylation [6] suggest that
some degree of overlap might be expected. The neuro-
pathological hallmarks of AD are, however, complex
phenotypes and APOE haplotype will be one of many
contributing factors (De Jager et al. [10] reported that
APOE ε4 could account for 13.9% of the variance in NP
burden observed in their participants). In addition, the
smaller samples assessed by De Jager et al. [10], Lunnon
et al. [12] and Smith et al. [61] may have been
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inadequately powered to detect any methylation differ-
ences driven by APOE haplotype. Differences in age and
methylation profiling platform are also likely to limit
comparability: the participants assessed in these studies
were much older (mean age > 75 years) than those
assessed in our study (mean age ~ 50 years) and array
differences mean that only two thirds of our DMP/DMR
probes were assessed. Two important corollaries of the
age difference are that brain-based studies are more
likely to (i) suffer from survivor bias and (ii) be better
suited to investigating end-of-disease processes. It is also
important to note that APOE is involved in multiple pro-
cesses, with APOE ε4 conferring risk for AD, at least in
part, via mechanisms that are not related to Aβ or tau
pathology. A recent study has indicated that APOE ε4-
associated breakdown of the blood-brain barrier in the
hippocampus and medial temporal lobe contributes to
APOE ε4-associated cognitive decline independently of
Aβ or tau [62].
The blood provides an easily accessible tissue that can
be repeatedly sampled to characterise pre-morbid
markers of risk. The extent to which it can provide
mechanistic insights into diseases that are considered
predominantly brain-based, however, is a perennial sub-
ject of debate. Cis meQTL effects tend to be highly cor-
related (r = 0.78) between the blood and the brain [63],
supporting the use of the blood to study the effects of
genetic risk factors for brain-based diseases. It is also im-
portant to note the increasing recognition of the role of
peripheral processes in conferring risk for AD [64]. As
the blood provides a conduit by which many circulating
factors (e.g. plasma proteins and microbial metabolites)
reach the brain and affect brain ageing [65], assessing
DNA methylation in the blood is likely to be informative
regarding systemic factors contributing to AD pathogen-
esis. Although APOE is synthesised separately in the
blood and the brain and neither APOE nor cholesterol
can cross the blood-brain barrier [66, 67], there is cross-
talk between brain and blood cholesterol via oxysterols
[67], levels of which vary by APOE ε2/ε3/ε4 haplotype
[68]. Peripheral hypercholesterolemia has been associ-
ated with increased oxysterol levels in the brain, which
have been implicated in with production and accumula-
tion of Aβ, increased neuroinflammation and neuronal
death [67].
The association between APOE genotype and AD var-
ies between populations [5], with studies in populations
of Hispanic and African ancestry often reporting attenu-
ated effect sizes for the ε4 allele compared to studies in-
volving European and Asian participants [69, 70].
Moreover, Rajabli et al. [70] have shown that genetic
variation local to APOE is likely to confer protection
from the effects of the ε4 allele in individuals of African
ancestry. As the participants in the present study were
of European ancestry, it should be noted that these find-
ings are likely to be European-specific and future studies
should assess their generalisability and relevance to AD
pathogenesis in other populations.
Conclusions
This is the first study to characterise epigenome-wide
DNA methylation differences between carriers of APOE
ε4 and ε2. In AD-free individuals, we identified several
methylation differences both at the APOE locus and in
the rest of the genome, which converge on lipid-related
pathways. Strengths of the study include the large sam-
ples available for EWAS analysis, the epigenome-wide
approach, the use of a well-phenotyped cohort with
genotype data and the avoidance of reverse causation by
studying AD-free participants. Future studies should in-
vestigate the causal relationship between APOE geno-
type, DNA methylation and lipid-related processes and
their role in AD pathogenesis.
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